Cevimeline

Pharmaceutical drug
  • C
Routes of
administrationBy mouth (capsules)ATC code
  • N07AX03 (WHO)
Legal statusLegal status
  • In general: ℞ (Prescription only)
Pharmacokinetic dataProtein binding<20%Identifiers
  • (2R,2R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane]
CAS Number
  • 107233-08-9 checkY
PubChem CID
  • 83898
DrugBank
  • DB00185 checkY
ChemSpider
  • 75707 checkY
UNII
  • K9V0CDQ56E
KEGG
  • D07667 checkY
ChEBI
  • CHEBI:3568 ☒N
ChEMBL
  • ChEMBL1201267 ☒N
CompTox Dashboard (EPA)
  • DTXSID801342027 DTXSID40274384, DTXSID801342027 Edit this at Wikidata
Chemical and physical dataFormulaC10H17NOSMolar mass199.31 g·mol−13D model (JSmol)
  • Interactive image
  • O1[C@H](SC[C@@]12CN3CCC2CC3)C
  • InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 checkY
  • Key:WUTYZMFRCNBCHQ-PSASIEDQSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's syndrome.

Medical uses

Cevimeline is used in the treatment of xerostomia (dry mouth)[1][2] and Sjögren's syndrome.[1] It increases the production of saliva.[2]

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[3]

Contraindications include asthma and angle closure glaucoma.[citation needed]

Mechanism of action

Cevimeline is a cholinergic agonist.[2] It has a particular effect on M1 and M3 receptors.[2] By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

See also

  • Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
  • Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect

References

  1. ^ a b Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, Tsubota K (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". American Journal of Ophthalmology. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277.
  2. ^ a b c d Fox RI, Fox CM (2019). "Management of Sjögren's". Dubois' Lupus Erythematosus and Related Syndromes (9th ed.). Elsevier. pp. 745–758. doi:10.1016/B978-0-323-47927-1.00060-8. ISBN 978-0-323-47927-1.
  3. ^ "Cevimeline". MedicineNet. Retrieved 12 October 2007.

External links

  • Evoxac (cevimeline HCl hydrate capsules) Full Prescribing Information
  • v
  • t
  • e
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators